| Hepatic IRE1α-XBP1 signaling promotes GDF15-mediated anorexia and body weight loss in chemotherapy | |
| 論文作者 | Tang, YX; Yao, T; Tian, X; Xia, XT; Huang, XX; Qin, ZW; Shen, Z; Zhao, L; Zhao, YP; Diao, BW; Ping, Y; Zheng, XX; Xu, YH; Chen, H; Qian, T; Ma, T; Zhou, B; Xu, SW; Zhou, QM; Liu, Y; Shao, ML; Chen, W; Shan, B; Wu, Y |
| 期刊/會議名稱 | JOURNAL OF EXPERIMENTAL MEDICINE |
| 論文年度 | 2024 |
| 論文類別 | |
| 摘要 | Platinum-based chemotherapy drugs can lead to the development of anorexia, a detrimental effect on the overall health of cancer patients. However, managing chemotherapy-induced anorexia and subsequent weight loss remains challenging due to limited effective therapeutic strategies. Growth differentiation factor 15 (GDF15) has recently gained significant attention in the context of chemotherapy-induced anorexia. Here, we report that hepatic GDF15 plays a crucial role in regulating body weight in response to chemo drugs cisplatin and doxorubicin. Cisplatin and doxorubicin treatments induce hepatic Gdf15 expression and elevate circulating GDF15 levels, leading to hunger suppression and subsequent weight loss. Mechanistically, selective activation by chemotherapy of hepatic IRE1 alpha-XBP1 pathway of the unfolded protein response (UPR) upregulates Gdf15 expression. Genetic and pharmacological inactivation of IRE1 alpha is sufficient to ameliorate chemotherapy-induced anorexia and body weight loss. These results identify hepatic IRE1 alpha as a molecular driver of GDF15-mediated anorexia and suggest that blocking IRE1 alpha RNase activity offers a therapeutic strategy to alleviate the adverse anorexia effects in chemotherapy. |
| 期 | 7 |
| 卷 | 221 |
| 影響因子 | 12.6 |
官方微信
